treatment group – Page 6 – Communicable Diseases Research

Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience

도심 안전망 병원에서 COVID-19에 대한 단일 클론 항체 주입의 구현 및 결과: South-Bronx 경험

Observational Study

Published on 2022-01-012022-09-12
Journal: Journal of the National Medical Association [Category] 임상, 진단,

Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone

Article

Published on 2021-12-302022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] Accuracy Admission Algorithm analyzed Classifier confounding variable corticosteroid pulse Corticosteroids COVID-19 COVID-19 pandemic Date death decrease died doses Efficacy Endpoint Evidence glucocorticoid group High-dose hospitalized COVID-19 patient hospitalized COVID-19 patients hospitalized patient Infectious diseases intubation Invasive mechanical ventilation machine machine learning machine learning classifiers methodology Methylprednisolone observational studies observational study Occurrence outcome Patient patients died pulse random reached required retrospective SARS-CoV-2 severe COVID-19 significant difference significantly single-center study subgroup analysis TCZ therapy Tocilizumab treated Treatment treatment group treatment groups variable was performed was tested were measured
[DOI] 10.3390/jcm11010198 PMC 바로가기 [Article Type] Article

A Case-Control Study for the Effectiveness of Oral Zinc in the Prevention and Mitigation of COVID-19

Medicine

Published on 2021-12-132022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] acute respiratory syndrome All participant anti-viral agents Blood caused clinic clinical parameter co-morbidities Community Comorbidities control group controlling Coronavirus disease-19 Course COVID-19 COVID-19 infection COVID-19 pandemic demographics determine develop diagnostics dose effective Effectiveness engage evaluated functions groups increase in indicate individual Infection lack likelihood management mitigate Mitigation morbidity and mortality Mortality multiple group Odds ratio oral pandemic participant Participants Population Prevent prevention Prophylactic Prophylaxis public health Randomized receive reduce Region renal replicate Research serologic assays severity severity of COVID-19 significantly higher single-blind symptomatic symptomatic SARS-CoV-2 infection the disease Therapies Treatment treatment group vaccination vaccine candidates variants of SARS-CoV-2 vitamin D levels Zinc zinc supplementation
[DOI] 10.3389/fmed.2021.756707 PMC 바로가기 [Article Type] Medicine

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Clinical Trial

Published on 2021-12-112022-10-05
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상,

[키워드] 1:1 95% CI absence Administered Adults adverse event age Analysis anaphylaxis assigned Bharat chronic conditions clinical Clinical efficacy clinical trial clinically clinics computer-generated Council COVID-19 COVID-19 infection Cutoff deaths dependent on distribution dose double-blind Efficacy evaluate Follow-up groups healthy hospital immunocompromising condition immunological immunosuppressive inactivated India interim analysis intramuscular dose investigators laboratory-confirmed median medical condition multicentre Nurse occurred Occurrence outcome outcomes participant Participants per-protocol population Phase 3 phase 3 trial Placebo placebo group placebo recipients placebo-controlled Primary outcome proportion raised randomisation randomised Randomly reactogenicity receive recipient recruited Registered registry reported Research safety population SARS-CoV-2 vaccine second dose Serious Adverse Event seronegative participant severity significant difference Sponsor stratified study population symptomatic symptomatic COVID-19 disease the vaccine therapy Toll-like receptor Treatment treatment group Trial Vaccine virion
[DOI] 10.1016/S0140-6736(21)02000-6 PMC 바로가기 [Article Type] Clinical Trial

Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients

사르데냐 다발성 경화증 환자에서 BNT162b2 백신에 대한 체액 반응에 대한 다양한 질병 수정 요법의 효과

Immunology

Published on 2021-12-092022-09-11
Journal: Frontiers in Immunology [Category] SARS, 진단, 치료법,

[키워드] Acetate addition affected age Alemtuzumab analyzed anti-SARS-CoV-2 vaccine Antibody titer Antibody titers BNT162b2 BNT162b2 vaccine Clinical data clinically COVID-19 COVID-19 vaccine demographic difference dimethyl fumarate Disease-modifying therapy drug Effect Factor fingolimod followed by fumarate Glatiramer healthy control humoral immune response Humoral immunity Humoral response immune response infected with SARS-CoV-2 interferon investigated linear Male sex mixed-effects model mRNA mRNA-based Multiple multiple sclerosis objective observé of BNT162b2 Older age Patient patients patients treated Prevent response Result Sardinian SARS-CoV-2 SARS-COV-2 infection sclerosis second dose sera serology Sex significantly significantly higher significantly lower smoking smoking status statistically significant difference Teriflunomide tested therapy Treatment treatment group treatment groups uninfected untreated patients vaccination Vaccine vaccine efficacy were assessed
[DOI] 10.3389/fimmu.2021.781843 PMC 바로가기 [Article Type] Immunology

The Effect of Isotonic Saline Nasal Lavages in Improving Symptoms in SARS-CoV-2 Infection: A Case-Control Study

Neurology

Published on 2021-12-062022-11-01
Journal: Frontiers in Neurology [Category] COVID-19,

[키워드] acute infections Administered adult subject Anosmia/ageusia average blocked colonize common cold control group controls coronavirus 2 COVID-19 decrease diagnosed Diagnosis ear Effect Efficacy enrolled eye Improving Infection isotonic Italy lavage Lugo nasal Nasal lavage nasal swab nasopharynx participant Patient performed positive positive swab questionnaire reducing respiratory Saline saline solution SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 patients significantly subject Swab Symptom Symptoms tested the SARS-CoV-2 Treatment treatment group two groups upper airway upper airways infection were infected
[DOI] 10.3389/fneur.2021.794471 PMC 바로가기 [Article Type] Neurology

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial

COVID-19 및 사이토카인 방출 증후군(COV-AID) 징후가 있는 환자에서 항인터루킨 약물의 효과: 요인, 무작위, 대조 시험

Randomized Controlled Trial

Published on 2021-12-012022-09-12
Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 진단,

[키워드] 95% CI assessment assigned baseline Belgium Block randomisation blockade C-reactive protein concentration center challenge Clinical improvement Complete Concentration Controlled trial COVID-19 Cytokine release syndrome D-dimer defined diagnosis of COVID-19 discharge drug Effect Efficacy Endpoint EudraCT evaluate Evidence factorial design failure ferritin fraction hazard ratio hospital hospitalised patient hypoxia hypoxic respiratory failure IL-1 IL-6 IL-6 blockade incidence intention-to-treat analysis intention-to-treat population interleukin International intravenously IQR lactate dehydrogenase less lymphopenia male mechanical ventilation median median age median time morbidity and mortality Mortality mortality risk Most patient multicentre Open-label oxygen PaO pathway Patient patients died patients with COVID-19 Primary outcome randomisation randomised Randomly receive Registered Safety safety population SARS-CoV-2 Serious Adverse Event serious infection serum single dose SOFA SOFA score Stratification study groups study outcome supplemental oxygen Symptom syndrome systemic cytokine therapeutic strategy Tocilizumab treatment group Trial were assessed with COVID-19
[DOI] 10.1016/S2213-2600(21)00377-5 PMC 바로가기 [Article Type] Randomized Controlled Trial

Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab

리툭시맙으로 치료받은 환자와 비교하여 인플릭시맙으로 치료받은 환자에서 COVID-19 발생률

Article

Published on 2021-12-012022-09-12
Journal: RMD Open [Category] SARS, 진단,

[키워드] 95% CI adjusted Autoimmune disease clinical collected COVID-19 COVID-19 in patient COVID-19 infections COVID-19 pandemic COVID-19 symptom determine diagnose enrolled Epidemiology Evolution First wave Fisher form incidence incidence of COVID-19 incidence rate independent Inflammatory infliximab inhibitors Intensive life-threatening manifestation mechanical ventilation Patient patients treated patients with COVID-19 PCR-confirmed Quality receiving Replication reported symptom rituximab RTX self-reported symptom severe COVID-19 Symptom Symptoms the disease Therapies TNF treated treatment group tumour necrosis factor validation cohort while with COVID-19
[DOI] 10.1136/rmdopen-2021-001711 PMC 바로가기 [Article Type] Article

Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial

Research Article

Published on 2021-11-232022-10-31
Journal: Evidence-based Complementary and Alternative Medicine : eCAM [Category] COVID-19,

Telephone‐based behavioral activation with mental imagery for depression: A pilot randomized clinical trial in isolated older adults during the Covid‐19 pandemic

Randomized Controlled Trial

Published on 2021-11-102022-10-04
Journal: International Journal of Geriatric Psychiatry [Category] MERS, SARS, 임상,

[키워드] Activation activity scheduling Adults adverse effect alleviate assigned behavioral activation clinically control condition control group Depression depressive symptom Diagnostic Criteria Efficacy exacerbated feasibility feasible Government greater decrease help imagery increased risk increases in individual investigated Isolation Mental mental health problem mental imagery MOST objective Older Older adults open‐label pandemic participant pilot study psychological treatment randomized clinical trial Randomly RCT Result social distancing social isolation Symptom symptoms of depression Treatment treatment group vulnerable persons
[DOI] 10.1002/gps.5646 PMC 바로가기 [Article Type] Randomized Controlled Trial